Anixa Biosciences, Inc.

NasdaqCM:ANIX Stock Report

Market Cap: US$94.7m

Anixa Biosciences Future Growth

Future criteria checks 0/6

Anixa Biosciences is forecast to grow earnings and revenue by 15.1% and 75% per annum respectively while EPS is expected to grow by 27.1% per annum.

Key information

15.1%

Earnings growth rate

27.1%

EPS growth rate

Biotechs earnings growth27.2%
Revenue growth rate75.0%
Future return on equityn/a
Analyst coverage

Low

Last updated22 Jan 2025

Recent future growth updates

Recent updates

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%?

Dec 19
Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%?

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Sep 12
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

May 23
We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

Jan 19
We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Oct 06
We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Apr 27
Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Jan 13
Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Sep 26
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

Aug 15

Anixa to get additional US patent linked to breast cancer vaccine technology

Jul 21

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jun 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

May 11

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Feb 24
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Oct 28
Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Our First Look At Anixa Biosciences

Sep 23

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

Jun 12
Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

OntoChem assigns Anixa covid-19 drug discovery project to MolGenie

May 07

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jan 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact

Dec 01

Earnings and Revenue Growth Forecasts

NasdaqCM:ANIX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
10/31/2027N/A-17-16-161
10/31/2026N/A-16-16-161
10/31/2025N/A-15-15-152
10/31/2024N/A-13-7-7N/A
7/31/2024N/A-12-8-8N/A
4/30/2024N/A-12-7-7N/A
1/31/20240-11-7-7N/A
10/31/20230-10-6-6N/A
7/31/20230-11-6-6N/A
4/30/20230-11-6-6N/A
1/31/2023N/A-12-7-7N/A
10/31/2022N/A-14-6-6N/A
7/31/20220-14-6-6N/A
4/30/20220-16-6-6N/A
1/31/20220-15-5-5N/A
10/31/20211-13-5-5N/A
7/31/20211-11-5-5N/A
4/30/20211-9-5-5N/A
1/31/20211-10-5-5N/A
10/31/2020N/A-10-6-6N/A
7/31/2020N/A-10-6-6N/A
4/30/2020N/A-9-5-5N/A
1/31/20200-9-6-5N/A
10/31/20190-12-5-5N/A
7/31/20190-15-5-4N/A
4/30/20191-18-5-5N/A
1/31/20191-17-4-4N/A
10/31/20181-14-4-4N/A
7/31/20181-10N/A-4N/A
4/30/20181-7N/A-4N/A
1/31/20180-5N/A-4N/A
10/31/20170-7N/A-4N/A
7/31/20171-6N/A-4N/A
4/30/20170-6N/A-3N/A
1/31/20170-7N/A-4N/A
10/31/20160-5N/A-3N/A
7/31/20160-5N/A-4N/A
4/30/20160-6N/A-3N/A
1/31/20160-7N/A-4N/A
10/31/20150-1N/A1N/A
7/31/20152-3N/A2N/A
4/30/20153-1N/A2N/A
1/31/20154-2N/A3N/A
10/31/20144-10N/A-2N/A
7/31/20143-9N/A-3N/A
4/30/20141-12N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANIX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANIX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANIX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANIX is forecast to have no revenue next year.

High Growth Revenue: ANIX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ANIX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 13:57
End of Day Share Price 2025/01/31 00:00
Earnings2024/10/31
Annual Earnings2024/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Anixa Biosciences, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.
Yi ChenH.C. Wainwright & Co.